Here are a few analogies for Palvella Therapeutics (PVLA):

• Like an early-stage Alexion Pharmaceuticals, but solely dedicated to developing therapies for rare genetic diseases.
• Like a clinical-stage Vertex Pharmaceuticals, but focused on a broader range of rare genetic diseases.
• Think of it as a startup Gilead Sciences that focuses exclusively on treatments for rare genetic diseases.

Palvella Therapeutics (PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases.

As a clinical-stage company, Palvella Therapeutics currently does not have commercialized products available for sale to end-users or distributors. Therefore, it does not have major customers in the traditional sense of selling therapies to other companies or individuals at this time.

Its primary activities are focused on research and development, including conducting clinical trials, with the aim of bringing potential therapies to market in the future.

Wes Kaupinen, President and Chief Executive Officer
Wes Kaupinen is the Founder, President, and Chief Executive Officer of Palvella Therapeutics. He previously served as CEO and director of Legacy Palvella from December 2015 to December 2024. Prior to founding Palvella, he was the Senior Vice President of Corporate Development and Commercialization at Insmed. Mr. Kaupinen was a Principal at Quaker Partners, a life sciences venture capital firm, and held prior roles at Apax Partners, Synthes, and J&J Cordis, indicating a pattern of managing companies backed by private equity firms. He has served as a board director or observer for over 10 companies, leading Series A investments in Intact Vascular and TELA Bio.

Matthew E. Korenberg, Chief Financial Officer
Matthew E. Korenberg was appointed Chief Financial Officer of Palvella Therapeutics in October 2024. He is a seasoned operational and financial leader with over 27 years of experience in biotech companies and healthcare investment banking. Before joining Palvella, Mr. Korenberg served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated and prior to that, as their Chief Financial Officer. He was also the founder, CEO, and a director of NeuroCircuit Therapeutics. Additionally, Mr. Korenberg worked as a Managing Director in healthcare investment banking at The Goldman Sachs Group, where he advised and financed biotechnology and pharmaceutical companies.

Jeff Martini, Ph.D., Chief Scientific Officer
Dr. Jeff Martini serves as the Chief Scientific Officer at Palvella Therapeutics. He brings nearly 20 years of leadership experience in R&D and corporate development. Before joining Palvella, Dr. Martini was the Executive Director of Business Development and Corporate Strategy at Marinus Pharmaceuticals.

Ashley Kline, Chief Commercial Officer
Ashley Kline was appointed Chief Commercial Officer of Palvella Therapeutics in May 2025. She has a proven track record in the commercialization of novel therapies for serious, rare diseases. Prior to Palvella, Ms. Kline served as Global Biotech Head and U.S. General Manager at Dompé Pharmaceuticals, where she led the successful launch of Oxervate®, which surpassed $500 million in annual U.S. sales by 2023. Her previous roles include positions on the commercial team at Genentech and as a consultant for Bain and Company.

Kathy Goin, Chief Operating Officer
Kathy Goin serves as the Chief Operating Officer at Palvella Therapeutics. She provides executive leadership in overseeing the company's operational infrastructure and strategic planning, leveraging her extensive experience in biotechnology operations management.

Palvella Therapeutics (PVLA), a clinical-stage biopharmaceutical company focused on rare genetic diseases, faces several key risks inherent to its stage of development and industry.

1. Clinical Trial Outcomes and Regulatory Approvals: As a pre-revenue, clinical-stage company, Palvella Therapeutics' viability is heavily dependent on the successful completion of its clinical trials and obtaining regulatory approvals for its product candidates, particularly QTORIN rapamycin. The regulatory approval process is lengthy, expensive, and uncertain, with no guarantee of success. A specific risk noted is that while the FDA has shown some flexibility for single-arm trials in rare diseases, regulatory agencies generally prefer randomized controlled trials. This could lead the FDA to require additional confirmatory studies or question the magnitude of efficacy from Phase 3 results if they are not robust. The company has not yet obtained regulatory approval for any products.
2. Commercialization and Market Acceptance: Even with successful clinical trials and regulatory approval, Palvella faces risks related to the commercial launch and market acceptance of its therapies. Introducing a new therapy requires demonstrating its value to payers to justify a premium price. The company's ability to achieve market acceptance is uncertain and depends on factors like safety, efficacy, pricing, and reimbursement. There is also a risk of competition from compounded topical rapamycin formulations, even though Palvella holds strong intellectual property for its anhydrous formulation.
3. Financial Risks and Ability to Fund Operations: Palvella Therapeutics has a limited operating history and has incurred substantial operating losses, with no revenue generated from product sales to date. While the company has recently raised capital and anticipates having sufficient funds to operate into the second half of 2027, it anticipates continuing losses for several years and there is no guarantee of achieving profitability. The company may need to seek additional capital to fund its operations beyond this period, particularly given potential significant commercialization expenses if QTORIN rapamycin is approved.

Palvella Therapeutics (symbol: PVLA) is a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic diseases, primarily through its QTORIN™ platform. The company's main product candidates and their estimated addressable markets in the U.S. are as follows:

• QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) is being developed for:
  • Microcystic Lymphatic Malformations (mLMs): The estimated addressable market is more than 30,000 diagnosed patients in the U.S..
  • Cutaneous Venous Malformations (cVMs): The estimated addressable market is more than 75,000 diagnosed patients in the U.S..
  • Clinically significant angiokeratomas: The estimated addressable market is more than 50,000 diagnosed patients in the U.S..
• QTORIN™ pitavastatin is being developed for:
  • Disseminated Superficial Actinic Porokeratosis (DSAP): The estimated addressable market is more than 50,000 diagnosed patients in the U.S..

Expected Drivers of Future Revenue Growth for Palvella Therapeutics (PVLA)

1. Commercial Launch of QTORIN™ rapamycin for Microcystic Lymphatic Malformations (mLM): Palvella Therapeutics anticipates the commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in 2027, following positive Phase 3 trial results reported in February 2026. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, with potential U.S. approval in the first half of 2027. This product has the potential to be the first FDA-approved therapy and a first-line standard of care for mLM, a serious, lifelong disease affecting an estimated over 30,000 diagnosed patients in the U.S. Palvella is actively preparing for launch, including a disease awareness campaign initiated in March 2026.
2. Potential Approval and Launch of QTORIN™ rapamycin for Cutaneous Venous Malformations (CVM): Following positive Phase 2 TOIVA study results for QTORIN™ rapamycin in cutaneous venous malformations announced in December 2025, Palvella requested a Preliminary Breakthrough Therapy Designation Advice meeting with the FDA in the first quarter of 2026. The company intends to commence a Phase 3 pivotal study in the second half of 2026, positioning QTORIN™ rapamycin as a potential first approved therapy and standard of care for CVM in the U.S.
3. Expansion of QTORIN™ rapamycin into New Indications: Palvella is expanding the development of QTORIN™ rapamycin to address additional rare skin and vascular conditions. In September 2025, the company expanded into clinically significant angiokeratomas, a condition affecting over 50,000 diagnosed U.S. patients with no FDA-approved therapies. QTORIN™ rapamycin received Fast Track Designation for angiokeratomas in December 2025, with a Phase 2 study expected to initiate in the second half of 2026. The company also plans to announce a fourth target clinical indication for QTORIN™ rapamycin in the second half of 2026.
4. Development and Potential Launch of QTORIN™ pitavastatin for Disseminated Superficial Actinic Porokeratosis (DSAP): In November 2025, Palvella introduced QTORIN™ pitavastatin as a new product candidate for disseminated superficial actinic porokeratosis. This is a premalignant genetic skin disease with no FDA-approved therapies, affecting an estimated more than 50,000 diagnosed patients in the U.S. Palvella plans to meet with the FDA in the first half of 2026 to discuss the proposed design of a Phase 2 clinical trial, with study initiation expected in the second half of 2026.

Share Issuance

• Palvella Therapeutics completed an upsized public offering in early March 2026, selling 1.84 million shares of common stock at $125.00 per share, which included the full exercise of the underwriters' option. This offering generated approximately $230 million in gross proceeds to fund the development of its QTORIN™ rapamycin and QTORIN™ pitavastatin programs.

Inbound Investments

• In January 2023, Palvella Therapeutics raised $37.70 million in a funding round.
• In December 2022, the company raised $9.70 million in a funding round.
• As of December 31, 2025, First Light Asset Management, LLC disclosed a beneficial ownership of 7.49% of Palvella's common stock, holding 887,031 shares. Funds associated with Biotechnology Value Fund and Mark N. Lampert beneficially owned approximately 7.1% of Palvella's outstanding common stock, totaling 879,009 shares, as of the same date.